Barclays
BRLI

Barclays’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Barclays’s Portfolio BRLI Stock Details BRLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8,800
Closed -$361K – 7371
2015
Q2 		$361K Sell
8,800
-11,200
-56% -$402K ﹤0.01% 3735
2015
Q1 		$700K Sell
20,000
-52,100
-72% -$1.76M ﹤0.01% 3288
2014
Q4 		$2.31M Sell
72,100
-11,100
-13% -$321K ﹤0.01% 2402
2014
Q3 		$2.33M Buy
83,200
+40,500
+95% +$1.23M ﹤0.01% 2526
2014
Q2 		$1.28M Buy
42,700
+33,300
+354% +$919K ﹤0.01% 3079
2014
Q1 		$254K Sell
9,400
-9,700
-51% -$254K ﹤0.01% 4572
2013
Q4 		$478K Buy
19,100
+8,200
+75% +$253K ﹤0.01% 4142
2013
Q3 		$316K Buy
10,900
+1,400
+15% +$38.9K ﹤0.01% 4585
2013
Q2 		$273K Buy
+9,500
New +$262K ﹤0.01% 4877

Other funds holding BRLI

SAM
Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return

Barclays's BRLI Position: Q3 2015 in Review

Barclays sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q3 2015, closing a stake of 47,438 shares — an estimated $1.94M sold.

Barclays first reported a position in BRLI in Q2 2013 and held it in 9 quarters. The position peaked at $2.29M in Q3 2014. 1 fund tracked by Wall St. Rank holds BRLI as of Q3 2015.

  • Barclays reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q3 2015 after selling out during the quarter.
  • Barclays sold 47,438 BIO-REFERENCE LABS INC-NEW- shares in Q3 2015, an estimated $1.94M.
  • Barclays first reported a position in BIO-REFERENCE LABS INC-NEW- in Q2 2013 and held it in 9 quarters.
  • Barclays's BIO-REFERENCE LABS INC-NEW- position peaked at $2.29M in Q3 2014.
  • 1 fund tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2015.

Based on Barclays's 13F filing for Q3 2015, filed 13 Nov 2015.